Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Jun 14;7(6):151.
doi: 10.3390/jcm7060151.

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Megan B Barnet  1   2   3 , Wendy A Cooper  4   5   6 , Michael J Boyer  7   8 , Steven Kao  9   10
Affiliations
Review

Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms

Megan B Barnet et al. J Clin Med. .

Abstract

Immune checkpoint inhibitors have shown efficacy in the treatment of non-small cell lung cancer (NSCLC) in the adjuvant, first- and subsequent-line settings. In metastatic disease, they provide hope of durable response where “best-case” scenario has long been inadequate. This progress has highlighted the immunogenic nature of NSCLC and invigorated research into immunotherapy in the field. In this review we consider the foundations of immunotherapy in NSCLC, canvass the current research and summarise the evidence guiding clinical practice.

Keywords: checkpoint inhibitors; immunotherapy; non-small cell lung cancer.

PubMed Disclaimer

Conflict of interest statement

Barnet reports non-financial support from Bristol Myers Squibb; Cooper is a scientific advisory board member for Bristol Myers Squibb, MSD, Astra Zeneca; Professor Boyer reports personal fees from Roche, Bristol Myers Squibb, MSD; Kao reports non-financial support from BMS, Boeringer, personal fees and non-financial support from Roche, Astra Zeneca, personal fees from Pfizer.

References

    1. Coley W.B., II Contribution to the Knowledge of Sarcoma. Ann. Surg. 1891;14:199–220. doi: 10.1097/00000658-189112000-00015. - DOI - PMC - PubMed
    1. Whitrow M. Wagner-Jauregg and fever therapy. Med. Hist. 1990;34:294–310. doi: 10.1017/S0025727300052431. - DOI - PMC - PubMed
    1. O’Malley W.E., Achinstein B., Shear M.J. Action of Bacterial Polysaccharide on Tumors. II. Damage of Sarcoma 37 by Serum of Mice Treated with Serratia Marcescens Polysaccharide, and Induced Tolerance. J. Natl. Cancer Inst. 1962;29:1169–1175. doi: 10.1111/j.1753-4887.1988.tb05376.x. - DOI
    1. Shear M.J., Perrault A. Chemical Treatment of Tumors. IX. Reactions of Mice with Primary Subcutaneous Tumors to Injection of a Hemorrhage-Producing Bacterial Polysaccharide1. J. Natl. Cancer Inst. 1944;4:461–476.
    1. Carswell E.A., Old L.J., Kassel R.L., Green S., Fiore N., Williamson B. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA. 1975;72:3666–3670. doi: 10.1073/pnas.72.9.3666. - DOI - PMC - PubMed

LinkOut - more resources